Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05732532 · ClinicalTrials.gov registry record · Phase 4
Steroids in Occipital Nerve Block for Treatment of Headache
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT05732532: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT05732532 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 120 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05732532, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
Currently there is limited evidence of benefit for the addition of steroids to occipital nerve blocks for treatment of headache, and not all steroids have been explored. The purpose of this research is to learn more about whether the addition of a specific kind of steroid (dexamethasone) provides any additional benefit to nerve blocks.
Primary Outcome
The change in the number of self-reported days subjects experienced headaches from baseline to 1 week.
Interventions
- DRUG Bupivacaine
- DRUG Dexamethasone
- DRUG Normal saline
- DRUG Lidocaine
- PROCEDURE Greater/lesser occipital nerve blocks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-02-17 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 4 |
What the finished NCT05732532 record still lists
NCT05732532 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 5 interventions - of which Bupivacaine is the first listed.
NCT05732532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05732532 about?
NCT05732532 is a clinical study titled "Steroids in Occipital Nerve Block for Treatment of Headache". Currently there is limited evidence of benefit for the addition of steroids to occipital nerve blocks for treatment of headache, and not all steroids have been explored. The purpose of this research is to learn more about whether the addition of a specific kind of steroid (dexamethasone) provides an...
What is the current status of trial NCT05732532?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2023-02-17. Estimated completion is 2025-06-01.
What interventions are being tested in trial NCT05732532?
The interventions under investigation include: Bupivacaine (DRUG), Dexamethasone (DRUG), Normal saline (DRUG), Lidocaine (DRUG), Greater/lesser occipital nerve blocks (PROCEDURE).
Who is sponsoring clinical trial NCT05732532?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05732532's enrollment target sits among peer trials
120 673rd of 2000 higher than 1,289 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI